Cargando…

Prediction of clinical response to omalizumab in moderate-to-severe asthma patients using the change in total serum IgE level

BACKGROUND: Omalizumab (OMA) is an effective anti-immunoglobulin E (IgE) treatment for moderate-to-severe asthma. However, predicting an individual’s response is difficult. Monitoring change of total serum IgE may be useful for predicting the response to OMA. The purpose of this study was to determi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Bohou, Huang, Minyu, Huang, Shuyu, Zeng, Xiaoli, Yuan, Yafei, Peng, Xianru, Zhao, Wenqu, Ye, Yanmei, Yu, Changhui, Liu, Laiyu, Ou, Chunquan, Cai, Shaoxi, Zhao, Haijin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797858/ https://www.ncbi.nlm.nih.gov/pubmed/33447398 http://dx.doi.org/10.21037/jtd-20-2073

Ejemplares similares

RAGE mediates airway inflammation via the HDAC1 pathway in a toluene diisocyanate-induced murine asthma model
por: Peng, Xianru, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
por: Tajiri, Tomoko, et al.
Publicado: (2023)

Inhibition of IgE and IgE/anti-IgE mediated responses in mast cells by Omalizumab
por: Kulka, M, et al.
Publicado: (2010)

Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
por: Pennington, Luke F., et al.
Publicado: (2016)

A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma
por: D’Amato, Gennaro, et al.
Publicado: (2007)

A Systemic Inflammatory Endotype of Asthma With More Severe Disease Identified by Unbiased Clustering of the Serum Cytokine Profile
por: Liang, Zhenyu, et al.
Publicado: (2016)

Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
por: Humbert, Marc, et al.
Publicado: (2013)

Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE
por: R, Divya, et al.
Publicado: (2020)

Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy
por: Kariyawasam, Harsha H, et al.
Publicado: (2020)

Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review
por: D’Amato, Gennaro, et al.
Publicado: (2014)

IgG and IgE Autoantibodies to IgE Receptors in Chronic Spontaneous Urticaria and Their Role in the Response to Omalizumab
por: Maronese, Carlo Alberto, et al.
Publicado: (2023)

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells
por: Chan, Marcia A, et al.
Publicado: (2013)

Current and future applications of the anti-IgE antibody omalizumab
por: Incorvaia, Cristoforo, et al.
Publicado: (2008)

Establishment and Evaluation of a Simplified Evaluation System of Acute Respiratory Distress Syndrome
por: Lu, Shubiao, et al.
Publicado: (2013)

Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab
por: Davies, Anna M., et al.
Publicado: (2017)

272 Gender and Different Prevalence in Asthma Treatment With Anti-IGE (Omalizumab)
por: Patella, Vincenzo, et al.
Publicado: (2012)

Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization
por: Mitropoulou, Alkistis N., et al.
Publicado: (2020)

A Case of Severe Asthma with Eosinophilic Otitis Media Successfully Treated with Anti-IgE Monoclonal Antibody Omalizumab
por: Okude, Azusa, et al.
Publicado: (2012)

Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma—A Romanian Perspective
por: Berghea, Elena Camelia, et al.
Publicado: (2021)

Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review
por: Lan, Jun, et al.
Publicado: (2022)

Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab
por: Roth, Michael, et al.
Publicado: (2015)

Serum free IgE guided dose reduction of omalizumab: a case report
por: Gon, Yasuhiro, et al.
Publicado: (2017)

Asthma diagnosis and treatment – 1015. Improvements in lung function in an indian population with IgE mediated asthma receiving omalizumab in a real-world setting
por: Guleria, Randeep, et al.
Publicado: (2013)

The AKT inhibitor MK2206 suppresses airway inflammation and the pro-remodeling pathway in a TDI-induced asthma mouse model
por: Cui, Haiyan, et al.
Publicado: (2020)

Reduction in oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma receiving omalizumab in a real-world setting
por: Braunstahl, Gert-Jan, et al.
Publicado: (2013)

The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry
por: Hutyrová, Beáta, et al.
Publicado: (2018)

Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels—A pilot study
por: Eckl‐Dorna, J., et al.
Publicado: (2017)

Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2019)

The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
por: Gasser, Pascal, et al.
Publicado: (2020)

IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms
por: Kuo, Be-Sheng, et al.
Publicado: (2022)

Levofloxacin Induced Toxic Epidermal Necrolysis: Successful Therapy with Omalizumab (Anti-IgE) and Pulse Prednisolone
por: Uzun, Rusen, et al.
Publicado: (2016)

The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?
por: Novosad, Jakub, et al.
Publicado: (2020)

Newly diagnosed asthma in China: initial severity and changes over a 1-year management period
por: Hu, Zhizhen, et al.
Publicado: (2022)

Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab
por: Saavedra, Michael C, et al.
Publicado: (2011)

Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect
por: Slevogt, Hortense, et al.
Publicado: (2022)

IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies
por: Barrios, D. M., et al.
Publicado: (2021)

Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry
por: Vaník, Petr, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vchi5r8j53f8ji55dd38l21av4